Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Holdings Increased by Swiss National Bank

Swiss National Bank increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 14.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,400 shares of the company’s stock after purchasing an additional 16,100 shares during the quarter. Swiss National Bank owned 0.21% of Syndax Pharmaceuticals worth $3,293,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Caxton Associates LP bought a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $615,000. Dimensional Fund Advisors LP raised its holdings in shares of Syndax Pharmaceuticals by 16.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,122,452 shares of the company’s stock worth $26,974,000 after purchasing an additional 161,346 shares in the last quarter. PFM Health Sciences LP raised its holdings in shares of Syndax Pharmaceuticals by 122.0% in the 3rd quarter. PFM Health Sciences LP now owns 1,289,073 shares of the company’s stock worth $30,976,000 after purchasing an additional 708,305 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of Syndax Pharmaceuticals by 27.0% in the 3rd quarter. Sofinnova Investments Inc. now owns 525,002 shares of the company’s stock worth $12,616,000 after purchasing an additional 111,574 shares in the last quarter. Finally, Psagot Value Holdings Ltd. Israel bought a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth approximately $127,000. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SNDX shares. The Goldman Sachs Group cut their price target on shares of Syndax Pharmaceuticals from $39.00 to $34.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Stifel Nicolaus started coverage on shares of Syndax Pharmaceuticals in a report on Monday, January 30th. They set a “buy” rating and a $37.00 price target on the stock. Citigroup cut their price target on shares of Syndax Pharmaceuticals from $32.00 to $31.00 in a report on Wednesday, May 10th. HC Wainwright upped their price objective on shares of Syndax Pharmaceuticals from $33.00 to $36.00 in a research note on Tuesday, May 9th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, April 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $33.86.

Insider Buying and Selling

In related news, Director Briggs Morrison sold 52,855 shares of the company’s stock in a transaction on Monday, April 10th. The shares were sold at an average price of $19.53, for a total transaction of $1,032,258.15. Following the completion of the sale, the director now directly owns 17,836 shares of the company’s stock, valued at approximately $348,337.08. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 158,564 shares of company stock valued at $3,354,684. Company insiders own 4.70% of the company’s stock.

Syndax Pharmaceuticals Stock Up 2.6 %

SNDX stock opened at $22.26 on Tuesday. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -9.24 and a beta of 1.11. Syndax Pharmaceuticals, Inc. has a 12 month low of $13.82 and a 12 month high of $29.86. The firm has a 50 day moving average of $21.01 and a two-hundred day moving average of $23.33.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) last posted its quarterly earnings data on Monday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.02. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.06 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

(Get Rating)

Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.